Study guide
6.4 Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity
CIH Certified Industrial Hygienist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The CIH Exam and How to Use This Guide
1.1 CIH Exam Format, Scoring, and Test-Day Logistics 1.2 Eligibility, Application Windows, Fees, and Certification Maintenance 1.3 The BGC Blueprint, Subject Areas, and a Calculation-First Study Plan
2 Chapter 2: Basic Science & Calculations
2.1 Gas Laws and Vapor Calculations 2.2 Unit Conversions: ppm, mg/m³, and Standard Temperature/Pressure 2.3 Fluid Mechanics and Airflow Fundamentals
3 Chapter 3: Air Sampling & Instrumentation
3.1 Active and Passive Air Sampling Strategies 3.2 Particulate and Aerosol Sampling 3.3 Direct-Reading Instruments and Calibration
4 Chapter 4: Analytical Chemistry & Lab Methods
4.1 Gas Chromatography and Mass Spectrometry 4.2 High-Performance Liquid Chromatography and Ion Chromatography 4.3 Spectroscopy and Elemental Analysis 4.4 Gravimetric, Microscopy, and Wet Chemical Methods 4.5 Laboratory Quality Assurance, Chain of Custody, and Desorption Efficiency
5 Chapter 5: Biostatistics & Epidemiology
5.1 Lognormal Distributions and Exposure Data Statistics 5.2 Upper Confidence Limits (UCL95) and Compliance Decision Rules 5.3 Epidemiological Study Designs and Measures of Association 5.4 Sampling Strategy: Sample Size, Power, and Worker Selection
6 Chapter 6: Toxicology & Biological Monitoring
6.1 Dose-Response Relationships and Points of Departure 6.2 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination 6.3 Aerosol Deposition, Clearance, and Respiratory Tract Dosimetry 6.4 Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity 6.5 Pulmonary Toxicology, Carcinogenicity, and Reproductive Hazards 6.6 OEL Frameworks, Classifications, and Excursion Limits 6.7 Chemical Mixtures and Extended Work-Shift OEL Adjustments 6.8 Biological Exposure Indices (BEIs) and Biomonitoring
7 Chapter 7: Biohazards & Indoor Environmental Quality
7.1 Mold, Fungi, and Microbial Contaminants 7.2 Infectious Agents, Bloodborne Pathogens, and Biosafety Levels 7.3 Indoor Environmental Quality (IEQ) Investigations 7.4 Sanitation, Potable Water, and Personal Hygiene Programs
8 Chapter 8: Community Exposure & Environmental Health
8.1 Clean Air Act Framework, NAAQS, and New Source Review 8.2 Hazardous Air Pollutants, CEMS, and EPA Reference Methods 8.3 Atmospheric Stability, Lapse Rates, and Plume Morphology 8.4 Gaussian Plume Modeling, Plume Rise, and Environmental Fate 8.5 HAZWOPER Scope, Mandates, and Training Tiers 8.6 Protection Levels, Site Zoning, Incident Command, and Decontamination 8.7 Water Pollution, Hazardous Waste, and Community Right-to-Know
9 Chapter 9: Health Risk Analysis & Hazard Communication
9.1 GHS Hazard Classification: Health and Physical Hazard Criteria 9.2 GHS Labels, Safety Data Sheets, and Trade Secret Rules 9.3 The AIHA Exposure Assessment Strategy and Similar Exposure Groups 9.4 Qualitative Exposure Profiling and the AIHA Risk Matrix 9.5 Quantitative Health Risk Characterization: HQ, HI, and ELCR 9.6 NIOSH Occupational Exposure Banding 9.7 Risk Communication and Reporting to Affected Parties
10 Chapter 10: Industrial Ventilation Principles & LEV Design
10.1 Elimination, Substitution, Isolation, Containment, and Process Change 10.2 LEV Hood Taxonomy and Capture Velocity Selection 10.3 Hood Airflow Equations, Entry Losses, and Hood Static Pressure 10.4 Particulate Transport Aerodynamics and Duct Sizing 10.5 Duct Friction, Fitting Losses, and System Balancing 10.6 Fan Categories and Pressure Dynamics Across the Fan 10.7 System Curves, the Fan Laws, and Density Corrections
11 Chapter 11: General Ventilation, Air Cleaning & Diagnostics
11.1 Dilution Ventilation Principles and Steady-State Modeling 11.2 Transient Purging and Air Distribution Geometry 11.3 Particulate Air Cleaning: Cyclones, Baghouses, Scrubbers, and ESPs 11.4 Gaseous Emission Control and Air Cleaner Selection 11.5 Ventilation System Troubleshooting and Testing
12 Chapter 12: Noise Measurement & Hearing Conservation
12.1 Acoustic Physics and Decibel Mathematics 12.2 Sound Propagation, Octave Bands, and Frequency Weighting 12.3 Noise Dose Metrics and OSHA versus ACGIH Criteria 12.4 Exchange Rates, Extended Shifts, and Dosimetry Field Protocols 12.5 Engineering Noise Controls and Hearing Protector Attenuation 12.6 Hearing Conservation Programs and Standard Threshold Shifts 12.7 Hand-Arm and Whole-Body Vibration
13 Chapter 13: Thermal Stress Assessment & Control
13.1 Wet Bulb Globe Temperature (WBGT) and Heat Stress Indices 13.2 Heat-Related Disorders, Acclimatization, and Work/Rest Regimens 13.3 Cold Stress Evaluation and Wind Chill
14 Chapter 14: Ionizing Radiation Protection
14.1 Ionizing Radiation Physics and Radioactive Decay Kinetics 14.2 Radiation Units, Radiobiology, and Health Effects 14.3 ALARA, Stay-Time, and the Inverse Square Law 14.4 Shielding Physics, Material Selection, and Gamma Constants 14.5 Radiation Detection Instruments and Spectrometry 14.6 Personnel Dosimetry, Dose Limits, and Contamination Surveys
15 Chapter 15: Non-Ionizing Radiation & Laser Safety
15.1 The Non-Ionizing Spectrum and Static/ELF Field Exposures 15.2 Radiofrequency and Microwave Exposure: SAR, Standards, and Surveys 15.3 Ultraviolet, Visible, and Infrared Radiation Hazards 15.4 Laser Safety Classifications and Optical Density Calculations 15.5 Illumination, Lighting Design, and Visual Performance
16 Chapter 16: Non-Engineering Controls & Personal Protective Equipment
16.1 Respiratory Protection Programs and Assigned Protection Factors 16.2 Maximum Use Concentration, Oxygen Deficiency, and Breathing Air 16.3 Particulate Filters, Sorbent Cartridges, and Change Schedules 16.4 Respirator Fit Testing Protocols 16.5 Chemical Protective Clothing and Dermal Exposure Control
17 Chapter 17: Ergonomics & Workstation Design
17.1 Soft-Tissue Biomechanics and WMSD Pathophysiology 17.2 Ergonomic Risk Factors and Their Interaction Effects 17.3 The Revised NIOSH Lifting Equation 17.4 RULA, REBA, the Strain Index, and the ACGIH HAL TLV 17.5 Anthropometry and Workstation Geometry 17.6 VDT Workstations, Hand Tool Design, and Administrative Ergonomics
18 Chapter 18: Work Environments & Industrial Processes
18.1 Welding Fume Emissions, Metal Fume Fever, and Cr(VI)/Manganese Toxicology 18.2 Foundry Operations and Hot Work Fire Prevention 18.3 Vapor Degreasing, Pickling, Electroplating, and Cyanide Baths 18.4 Spray Coatings, Isocyanates, and Semiconductor Manufacturing 18.5 Confined Spaces and High-Hazard Industrial Operations 18.6 Asbestos, Lead, and Silica: Regulated Substance Programs 18.7 Abrasive Blasting and Surface Preparation
19 Chapter 19: IH Program Management & Professional Ethics
19.1 The BGC Code of Ethics: Canons and Enforcement 19.2 Professional Liability, Standard of Care, and Expert Testimony 19.3 Occupational Health & Safety Management Systems (ISO 45001, ANSI Z10) 19.4 Exposure Records Access and Medical Surveillance 19.5 OSHA Injury and Illness Recordkeeping and Enforcement
6.4 Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity
Key Takeaways Explain This Topic AI
The liver is the primary site of xenobiotic biotransformation and therefore the primary site of bioactivation injury: carbon tetrachloride and chloroform are hepatotoxic only after P450 metabolism.
The kidney concentrates filtrate, so nephrotoxicants such as cadmium, mercury, and halogenated hydrocarbons reach far higher tubular concentrations than plasma concentrations; urinary beta-2-microglobulin marks early tubular damage.
Central nervous system depressants (most solvents) produce acute narcosis, while peripheral neuropathy is characteristic of n-hexane, methyl n-butyl ketone, acrylamide, arsenic, and lead.
Benzene is the classic hematotoxicant, causing aplastic anaemia and acute myelogenous leukaemia; lead inhibits delta-aminolevulinic acid dehydratase and ferrochelatase, producing basophilic stippling and anaemia.
Last updated: August 2026
Hepatic, Renal, Neurologic, and Hematologic Target Organ Toxicity
Workplace chemicals produce distinct patterns of adverse health effects depending on their chemical structure, metabolic fate, receptor binding affinity, and the physiological vulnerability of specific organ systems. On the CIH examination, industrial hygienists must demonstrate deep competency in recognizing target organs, identifying toxic intermediate metabolites, understanding cellular mechanisms of action, and applying cancer classification schemas.
1. Hepatotoxicity & Hepatic Pathophysiology
The liver is the primary site of xenobiotic metabolism and clearance, rendering it highly susceptible to chemical-induced injury. The hepatic acinus is functionally divided into three distinct microvascular zones: +-------------------------------------------------------------+
- | THE HEPATIC ACINUS ZONES |
- +-------------------------------------------------------------+
- | Portal Triad (Hepatic Artery, Portal Vein, Bile Duct) |
- | | |
- | v |
- | [ ZONE 1: Periportal Zone ] |
- | - Highest oxygenation, highest glutathione (GSH) |
- | - High gluconeogenesis, fatty acid oxidation |
- | - Primary target: Allyl alcohol, Iron overload, Phosphorus |
- | | |
- | v |
- | [ ZONE 2: Midzonal Zone ] |
- | - Intermediate oxygen and metabolic enzymes |
- | | |
- | v |
- | [ ZONE 3: Centrilobular / Perivenous Zone ] |
- | - Lowest oxygenation (predisposed to hypoxia) |
- | - HIGHEST CYP450 concentration (CYP2E1, CYP3A4) |
- | - Primary target: Carbon tetrachloride (CCl4), Chloroform, |
- | Acetaminophen, Halothane, Bromobenzene |
- | | |
- | v |
- | Central Vein (Blood drains to systemic circulation) |
- +-------------------------------------------------------------+
- Patterns and Mechanisms of Hepatotoxicity
Centrilobular Necrosis (Zone 3):
Carbon Tetrachloride (CCl4): Diffuses into centrilobular hepatocytes where CYP2E1 cleaves a carbon-chlorine bond to generate the highly unstable trichloromethyl radical (·CCl3) . In the presence of oxygen, this reacts to form the trichloromethylperoxy radical (·OOCCl3) . CCl 4 → CYP2E1 ⋅ CCl 3 + Cl − → O 2 ⋅ OOCCl 3 \text{CCl}_4 \xrightarrow{\text{CYP2E1}} \cdot\text{CCl}_3 + \text{Cl}^- \xrightarrow{\text{O}_2} \cdot\text{OOCCl}_3 CCl 4 CYP2E1 ⋅ CCl 3 + Cl − O 2 ⋅ OOCCl 3 These free radicals initiate a chain reaction of lipid peroxidation in the polyunsaturated fatty acids of the endoplasmic reticulum and mitochondrial membranes, destroying calcium homeostasis and resulting in acute cell lysis and massive centrilobular hepatic necrosis.
Acetaminophen (Paracetamol): Therapeutic doses undergo Phase II glucuronidation and sulfation. Overdose or CYP2E1 induction (e.g., in chronic alcoholics) saturates Phase II pathways, routing excess drug through CYP2E1 to generate N-acetyl-p-benzoquinone imine (NAPQI) . NAPQI rapidly depletes hepatic glutathione (GSH) ; once GSH is depleted by > 70%, NAPQI binds covalently to vital mitochondrial proteins, causing necrotic cell death.
Steatosis (Fatty Liver):
Accumulation of triglycerides within hepatocytes exceeding 5% of liver weight.
Induced by ethanol , carbon tetrachloride , and hydrazine through inhibition of very-low-density lipoprotein (VLDL) synthesis and impaired lipid secretion.
Canalicular Cholestasis:
Impaired bile flow resulting in jaundice, elevated serum bilirubin, and elevated alkaline phosphatase (ALP).
Induced by methylene dianiline (MDA) (historical "Epping jaundice"), chlorpromazine , and anabolic steroids.
Hepatic Angiosarcoma:
Rare, highly malignant endothelial cell vascular tumor of the liver.
Pathognomonic occupational etiology: Vinyl chloride monomer (CH2=CHCl) exposure during polyvinyl chloride (PVC) polymerization.
2. Nephrotoxicity & Renal Clearance Pathology
The kidneys receive approximately 20-25% of resting cardiac output , resulting in massive daily delivery of circulating xenobiotics. Concentration of solutes along the nephron and active tubular transport systems make the renal cortex—specifically the proximal convoluted tubule —the primary target for chemical nephrotoxicity. +-------------------------------------------------------------+
- | NEPHRON TOXICITY TARGET SITES |
- +-------------------------------------------------------------+
- | |
- | GLOMERULUS ----------------> Glomerular Basement Membrane |
- | Target: Immune complexes, HCFC|
- | |
- | PROXIMAL CONVOLUTED TUBULE > S1, S2, S3 Segments |
- | - Highest transport activity |
- | - High CYP450 & beta-lyase |
- | - Target: Cadmium, Lead, |
- | Mercury, Halogenated HC, |
- | Aminoglycosides |
- | |
- | LOOP OF HENLE / MEDULLA ---> Hyperosmotic Papillary Bed |
- | Target: Analgesics, Fluoride |
- | |
- | COLLECTING DUCT -----------> Water Reabsorption |
- | Target: Amphotericin B, Lead |
- +-------------------------------------------------------------+
- Major Nephrotoxic Agents & Molecular Mechanisms
Cadmium (extCd):
Ingested or inhaled cadmium binds to metallothionein (MT) in the liver, forming a low-molecular-weight Cd-MT complex.
The Cd-MT complex is released into blood, filtered freely through the glomerulus, and endocytosed by proximal tubular epithelial cells .
In lysosomes, the protein is degraded, releasing free Cd²⁺ ions that destroy mitochondrial function and cause tubular necrosis.
Clinical Indicator: β2-microglobulinuria (failure of the damaged proximal tubule to reabsorb low-molecular-weight proteins), followed by glucosuria, aminoaciduria, and irreversible chronic renal failure (Itai-itai disease).
Inorganic Lead (extPb):
Accumulates in proximal tubular lining cells, forming pathognomonic dense intranuclear inclusion bodies (lead-protein complexes).
Induces Fanconi-like syndrome (proximal tubular dysfunction manifesting as glycosuria, aminoaciduria, and phosphaturia), hyperuricemia ("saturnine gout"), and chronic tubulointerstitial nephritis with renal fibrosis.
Halogenated Hydrocarbons (Trichloroethylene, Hexachlorobutadiene):
Undergo hepatic glutathione conjugation to form cysteine S-conjugates.
These conjugates travel to the proximal tubule where renal cysteine conjugate β-lyase bioactivates them into highly reactive, nephrotoxic, mutagenic thioketenes and thiol intermediates.
3. Neurotoxicity: Central vs. Peripheral Nervous Systems
Because mature neurons cannot divide and regenerate, and have high metabolic rates, the nervous system is acutely vulnerable to toxic disruption.
Central Nervous System (CNS) Toxicants
Organic Solvents (Acute CNS Depression / Narcosis):
Aliphatic, aromatic, and chlorinated solvents (toluene, xylene, acetone, trichloroethylene) dissolve into lipid neuronal membranes.
Enhance inhibitory GABAA receptor neurotransmission and suppress excitatory NMDA glutamate receptors, inducing concentration-dependent intoxication, ataxia, slowed reaction time, narcosis, and fatal respiratory arrest.
Chronic high-level solvent exposure produces Chronic Solvent-Induced Encephalopathy (CSE) (also termed "Painter's Syndrome"), characterized by irreversible cognitive decline, psychomotor slowing, and memory loss.
Manganese (extMn):
Inhalation of manganese fumes (welding on high-tensile steel, smelting) causes accumulation in the basal ganglia , specifically the globus pallidus and substantia nigra .
Induces "Manganism" —characterized initially by emotional lability and psychosis ("manganese madness"), progressing to irreversible Parkinson-like extrapyramidal symptoms: masked facies, severe resting tremor, cogwheel rigidity, and cock-walk gait.
Carbon Disulfide (CS2):
Viscose rayon manufacturing and rubber solvent.
Causes severe CNS psychosis, depression, extrapyramidal parkinsonian syndrome, accelerated coronary and cerebral atherosclerosis, and distal sensorimotor polyneuropathy.
Peripheral Nervous System (PNS) Axonopathies & Neuropathies +-------------------------------------------------------------+
- | n-HEXANE AXONAL NEUROPATHY MECHANISM |
- +-------------------------------------------------------------+
- | |
- | n-Hexane (Parent hydrocarbon) |
- | | |
- | v (CYP450 omega-1 oxidation) |
- | 2,5-Hexanedione (2,5-HD, Active gamma-diketone) |
- | | |
- | v (Reacts with epsilon-amino groups of Lysine) |
- | Pyrrole Adduct Formation on Neurofilament Proteins |
- | | |
- | v (Auto-oxidation & Covalent Crosslinking) |
- | Crosslinked Neurofilament Aggregates |
- | | |
- | v (Blocked Anterograde Fast Axonal Transport) |
- | Giant Axonal Swelling (Proximal to Nodes of Ranvier) |
- | | |
- | v |
- | Distal Axonal Degeneration ("Dying-Back" Neuropathy) |
- | - Symmetrical "Glove-and-Stocking" Sensorimotor Deficit |
- +-------------------------------------------------------------+
n-Hexane and Methyl n-Butyl Ketone (MnBK):
Both are metabolized into the identical toxic γ-diketone: 2,5-hexanedione (2,5-HD) .
2,5-HD reacts with lysine residues on neurofilaments to generate pyrrole rings , which oxidize and crosslink adjacent neurofilaments.
Neurofilaments aggregate and occlude axonal transport, producing giant axonal swellings proximal to the nodes of Ranvier, followed by distal axonal retraction and secondary myelin breakdown ( distal dying-back axonopathy ).
Workers experience progressive, symmetrical, distal sensorimotor deficits ("glove-and-stocking" paresthesia, loss of deep tendon reflexes, motor weakness).
Inorganic Lead (Motor Neuropathy):
In adults, lead targets peripheral motor nerves, particularly the radial and peroneal nerves.
Manifests as classic wrist drop and foot drop without prominent sensory loss.
Acrylamide:
Vinyl monomer causing central-peripheral distal axonopathy via inhibition of kinesin-based retrograde and anterograde axonal transport.
Organophosphates (OPIDN):
Certain organophosphorus compounds (e.g., TOCP — tri-o-cresyl phosphate) induce Organophosphate-Induced Delayed Polyneuropathy (OPIDN) occurring 1-3 weeks post-exposure.
Mechanism: Inhibition and subsequent "aging" of Neuropathy Target Esterase (NTE) in axonal membranes, entirely independent of acetylcholinesterase inhibition.
- 4. Hematotoxicity & Blood-Forming Organs
- Benzene Hematotoxicity: Aplastic Anemia and Leukemia
Benzene is a myelotoxic leukemogen regulated by OSHA under 29 CFR 1910.1028 (PEL = 1 ppm, Action Level = 0.5 ppm): Benzene → Hepatic CYP2E1 Phenol → CYP2E1 Hydroquinone and Catechol \text{Benzene} \xrightarrow{\text{Hepatic CYP2E1}} \text{Phenol} \xrightarrow{\text{CYP2E1}} \text{Hydroquinone and Catechol} Benzene Hepatic CYP2E1 Phenol CYP2E1 Hydroquinone and Catechol Hydroquinone → Bone Marrow Myeloperoxidase 1 , 4 -Benzoquinone \text{Hydroquinone} \xrightarrow{\text{Bone Marrow Myeloperoxidase}} \mathbf{1,4\text{-Benzoquinone}} Hydroquinone Bone Marrow Myeloperoxidase 1 , 4 -Benzoquinone
1,4-Benzoquinone and its free radicals selectively attack bone marrow CD34+ hematopoietic stem/progenitor cells .
Induces topoisomerase II inhibition, oxidative DNA strand breaks, and specific clonal chromosomal aberrations (monosomy 5, monosomy 7, del(5q), del(7q), trisomy 8).
Clinical progression: Progressive pancytopenia → Aplastic Anemia → Myelodysplastic Syndrome (MDS) → Acute Myeloid Leukemia (AML) .
Carbon Monoxide: Carboxyhemoglobin & Hypoxia
Carbon monoxide (CO) binds to the ferrous (Fe²⁺) heme iron of hemoglobin with an affinity approximately 210 to 250 times greater than oxygen , forming carboxyhemoglobin (COHb) .
Dual Mechanism of Toxicity:
Occupies oxygen-binding sites, reducing oxygen-carrying capacity of blood.
Left-shifts the oxyhemoglobin dissociation curve (allosteric cooperativity alteration), locking remaining oxygen onto hemoglobin molecules and severely impairing oxygen offloading to hypoxic peripheral tissues.
Directly inhibits cytochrome c oxidase (Complex IV) in mitochondrial electron transport.
Arsine Gas (AsH3): Intravascular Hemolysis
Generated when arsenic-contaminated ores, dross, or metals contact acid.
Arsine binds to erythrocyte membrane spectrin proteins, triggering massive, acute intravascular hemolysis .
Triad of clinical signs: Hemoglobinuria (dark red/black urine), jaundice, and acute oliguric renal failure from massive tubular obstruction by hemoglobin casts.
Methemoglobinemia
Induced by aromatic amines ( aniline , toluidine ) and nitro compounds ( nitrobenzene ).
Oxidizes normal ferrous iron (Fe²⁺) in hemoglobin to ferric iron (Fe³⁺), creating methemoglobin (MetHb) , which cannot bind oxygen.
Clinical Presentation: Cyanosis unresponsive to supplemental oxygen ("chocolate brown blood"). Blood MetHb > 10% produces cyanosis; > 50% produces coma and seizures.
Specific Antidote: Intravenous Methylene Blue (reduces Fe³⁺ back to Fe²⁺ via NADPH-methemoglobin reductase).